The A2L intermediate gene product is required for in vitro transcription from a vaccinia virus late promoter.
Previously, the in vitro late transcription system of vaccinia virus was resolved into four components: the 17- and 30-kDa products of the A1L and G8R intermediate genes, respectively, the viral DNA-dependent RNA polymerase, and an unmapped factor sedimenting at 32 to 38 kDa. Another protein, the 26-kDa product of the A2L open reading frame was predicted to be a late transcription factor on the basis of a transient-expression assay but was not recognized as being necessary for transcriptional activity in vitro. We now report that both the unmapped factor and the 26-kDa protein are required for transcription from a vaccinia virus late promoter in vitro. Since the 26-kDa protein has now been shown to be a trans-activator of late transcription and it is the product of a known gene, we suggest that it be designated VLTF-3.
Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, D.C. 20306-6000, USA.
A E
AE
Hubbs
C F
CF
Wright
D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D004279:DNA, Viral; D015967:Gene Expression Regulation, Viral; D017781:Genes, Immediate-Early; D006367:HeLa Cells; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D008969:Molecular Sequence Data; D009154:Mutation; D017924:Nucleopolyhedroviruses; D011401:Promoter Regions, Genetic; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic; D014616:Vaccinia virus / Q000235:genetics*; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism
C081260:A2L protein, Vaccinia virus; D004279:DNA, Viral; D011993:Recombinant Fusion Proteins; D015534:Trans-Activators; D014764:Viral Proteins; D006918:Hydroxyurea